Aspects of treatment of crisis in myasthenia gravis.
D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D002800:Cholinesterase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D004342:Drug Hypersensitivity; D004491:Edrophonium; D004630:Emergencies / Q000628:therapy; D005260:Female; D006801:Humans; D007251:Influenza, Human / Q000150:complications; D007362:Intensive Care Units; D007442:Intubation, Intratracheal; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic; D009157:Myasthenia Gravis / Q000150:complications* / Q000188:drug therapy; D009469:Neuromuscular Junction; D010276:Parasympatholytics / Q000008:administration & dosage / Q000009:adverse effects*; D011014:Pneumonia / Q000150:complications; D012121:Respiration, Artificial; D012129:Respiratory Function Tests; D012141:Respiratory Tract Infections / Q000150:complications*; D014140:Tracheotomy / Q000009:adverse effects
D000900:Anti-Bacterial Agents; D002800:Cholinesterase Inhibitors; D010276:Parasympatholytics; D004491:Edrophonium